Stockstowatch
SLT.N0000Forming a triangle pattern in daily chart. SLT is also protecting in 200EMA line.
Disclaimer: The information and analysis provided in this publication are for educational purposes only and should not be construed as financial advice or recommendations to buy, sell, or hold any securities. The author and TradingView are not responsible for any investment decisions made based on the content presented herein. Always consult a financial professional before making any investment decisions.
Balaji Amines looking good after a long time. Balaji Amines Ltd., INDIA is an ISO 9001: 2015 certified company, specialised in manufacturing Methylamines, Ethylamines, Derivatives of Specialty Chemicals and Pharma Excipients. These have been their main products, they additionally manufacture derivatives, which are downstream products for various Pharma /Pesticide industries apart from user specific requirements.
Negative aspects of the company are de-growth in revenue and profit and high PE 42.1. Positive aspects of the company are low debt, net cash flow from operating activities increasing, MFs increasing stake and Zero promoter pledge.
Entry can be taken after closing above 2428. Targets in the stock will be 2493 and 2553. The long-term target in the stock will be 2588 and 2600+. Stop loss in the stock should be maintained at Closing below 2130.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
Aptus may get a Techincal impetusAptus Value Housing Finance India Ltd is a Home Loan Company. Aptus has been formed to primarily address the housing finance needs of self-employed, belonging to Low and Middle Income Families primarily from semi urban and rural markets.
Negative aspects of the company are promoter decreasing the stake and high PE 29.7 of the company. Positive aspect of the company are good quarterly growth, FIIs and MFs increasing stake in the company.
Entry can be taken after closing above 351. Targets in the stock will be 360, 367 and 375. The long-term target in the stock will be 384 and 392. Stop loss in the stock should be maintained at Closing below 326 or 313 depending upon your risk taking ability.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
MPW's $4.60 Price Target After Bullish BreakoutTechnical Analysis
MPW has been showing some solid bullishness out of the buy zone. There has been 6 consecutive green weekly candles so far including this week. MPW is forming a bullish breakout above this light blue trendline and orange resistance zone. I think there will be a pullback at some point, but for now the trend is still bullish and $4.60 is the key price target on this move up.
Medical Properties Trust (MPW): Navigating Liquidity And Strategic Asset Management
Medical Properties Trust Inc. (NYSE: MPW) recently shared insights into its financial health and strategic direction during its fourth quarter 2023 earnings call. With a focus on creating significant liquidity and managing its diverse portfolio of healthcare facilities, the company outlined its plan to navigate through current challenges and capitalize on its strengths. This blog delves into the key takeaways from the earnings call, highlighting both the bullish and bearish aspects of MPW’s strategy and performance.
Strategic Initiatives For Enhanced Liquidity
MPW’s CEO, Edward Aldag Jr., unveiled a capital allocation strategy aimed at generating at least $2 billion in liquidity by 2024. This ambitious plan involves the sale of Australian facilities and hospitals to Prime Healthcare Services, showcasing MPW’s proactive approach to capital management. These strategic asset sales, alongside ongoing opportunities, underscore the company’s commitment to financial flexibility and growth.
Addressing Challenges With Optimism
Despite facing issues with Steward Health Care System’s cash collections, MPW remains optimistic. The company is actively working on re-tenanting Steward properties, reflecting confidence in its ability to manage tenant-related challenges effectively. Additionally, the improved performance of Prospect Medical Holdings adds a layer of positivity, reinforcing MPW’s diversified portfolio’s strength.
A Look At The Bearish And Bullish Highlights
Bearish Insights:
The distressed situation with Steward has necessitated strategic re-tenanting and asset sales to ensure consistent rent payments.
A significant write-down of $90 million for loans to Steward underscores the financial challenges faced.
Concerns remain for an operator within the cash accounting pool, projecting no financial support due to low coverage.
Bullish Perspectives:
Interest from multiple potential tenants for Steward properties indicates robust demand for MPW’s assets.
The company’s European and American portfolios, including Circle Health and Priory, demonstrate strong performance.
Prospect Medical Holdings’ turnaround contributes to the positive outlook, highlighting potential for growth.
Future Outlook And InvestingPro Insights
Looking ahead, MPW is poised to achieve its strategic objectives, bolstered by a focus on sustaining community health through acute care hospitals. The company’s strategic sales and financing plans aim to navigate the complex financial landscape successfully.
From an investment perspective, MPW presents a mixed bag of opportunities and challenges. According to InvestingPro data, the company boasts a market cap of $2.28 billion USD and an appealing dividend yield of 15.79%. The aggressive share buyback program and low Price / Book multiple suggest that MPW may be undervalued, offering potential for income generation and price appreciation.
Conclusion
Medical Properties Trust Inc. is at a pivotal point, with strategic initiatives in place to enhance liquidity and manage its portfolio effectively. While challenges remain, particularly with certain tenants, the company’s optimistic approach and strategic sales indicate a forward-looking perspective. For investors, MPW’s current valuation and dividend yield may offer attractive opportunities, especially for those focused on income generation and value investing. As MPW navigates its strategic path, its ability to adapt and capitalize on its strengths will be crucial in driving future success.
NVAX Bullish Breakout After Settlement of Gavi DisputeNVAX Technical Analysis
NVAX has been showing some solid bullishness since settling the Gavi dispute. NVAX is pumping out of the buy zone, and there has been a bullish breakout above the light blue resistance line. The key price target ahead is the green resistance line ($6.36), a yellow resistance zone ($8.20 to $8.46), and a red resistance line ($10.23). I have $3.54 to $3.93 as my new buy zone. I think there are likely to be more buy opportunities around there. For now the price is bullish and trending up.
Novavax Reaches Settlement With Gavi, Paving The Way Forward
In a significant development announced on February 22, Novavax, a key player in the COVID-19 vaccine market, has reached a settlement with Gavi, the Vaccine Alliance, resolving a contentious dispute over unfulfilled vaccine orders. This settlement marks a critical juncture for Novavax, alleviating financial uncertainties and setting the stage for future growth and collaborations.
The Dispute Resolution
Novavax has committed to repaying Gavi a minimum of $475 million, either in cash or through vaccine supplies, by the end of 2028. This agreement comes as a resolution to a conflict stemming from Novavax’s inability to deliver on a contract for up to 350 million doses of its COVID-19 vaccine, despite Gavi’s advance payment of $700 million in 2021 and 2022.
Impact On Novavax
The announcement led to a significant surge in Novavax’s stock price, which climbed by 23.2% to $4.91 following the news. This is a noteworthy rebound for the company, whose stock had previously plummeted by nearly 60% amid concerns over its operational viability. The settlement not only removes a major financial overhang but also enhances Novavax’s appeal as a business partner, according to CEO John Jacobs.
Settlement Terms
Under the terms of the settlement, Novavax has made an upfront payment of $75 million to Gavi, with additional payments of $80 million annually in quarterly installments scheduled through 2028. These payments can be adjusted if Gavi opts to receive vaccines instead of cash. The agreement also includes provisions for extra vaccine credits, potentially worth up to $225 million, should demand exceed the annual $80 million mark.
Strategic Implications For Novavax
The resolution of this dispute is pivotal for Novavax, offering a path to stabilize its financials and focus on future endeavors. CEO John Jacobs highlighted the settlement’s role in mitigating the risk of a substantial one-time payment and enabling better cash flow management. The estimated present value of the settlement ranges between $300 and $400 million, signaling a strategic financial recalibration for the company.
Looking Ahead
With new leadership at the helm of both Novavax and Gavi, this agreement signals a fresh start and a mutual focus on future collaborations and initiatives. Novavax is already eyeing new revenue streams, with plans to introduce a combination COVID-flu vaccine by 2026 and capitalize on a malaria vaccine developed in partnership with the Serum Institute of India. These initiatives, coupled with significant cost reductions and operational streamlining, underscore Novavax’s commitment to overcoming past challenges and seizing future opportunities.
Conclusion
In conclusion, the settlement between Novavax and Gavi not only resolves a major dispute but also highlights the resilience and strategic pivoting of Novavax amidst the complexities of the global vaccine landscape. As the company navigates beyond its COVID-centric phase, this development offers promising insights into its potential for innovation, growth, and partnerships in the years to come.
EUREKA FORBES (POLE & FLAG) Eureka Forbes is getting a lot of bulk deals from big investors and it's a sign it can break with good volumes in coming weeks.
Target 600-700-780-900
NOTE: I'm not a SEBI REG. Study before investing.
Adani Wilmar looking Oil RichAdani Wilmar Ltd. is a manufacturer of Edible Oil, Vanaspati, and Specialty Fats. The Company offers soybean oil, sesame oil, sunflower oil, cottonseed oil, groundnut oil, mustard oil, groundnut oil, and coconut oil, as well as vegetable ghee. It serves households and institutional buyers. It offers products through distributors, super stockists, brokers, and other trade associates. It exports products to The Middle East countries, South East Asian countries, Africa, Ukraine, and Ghana.
Adani Wilmar Ltd CMP is 389.95. The Negative aspects of the company are High Valuation (P.E. = 597.3), Declining annual net profit, declining cash from operations annual, Promoter Holding decreasing. The positive aspects of the company are No debt, zero promoter pledge, FIIs are increasing stake, MFs are increasing stake.
Entry for paper trading can be taken after closing above 396. Targets in the stock will be 412 and 423. The long-term target in the stock will be 443 and 461. Stop loss in the stock should be maintained at Closing below 335.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
Anupam Rasayan Rising after forming a bottom.Anupam Rasayan India Ltd. is one of the leading companies in India engaged in the custom synthesis and manufacturing of specialty chemicals. It has two distinct business segments that manufacture life science related specialty chemicals including products related to agrochemicals, personal care and pharmaceuticals, and other specialty chemicals, including specialty pigment and dyes, and polymer additives.
Anupam Rasayan India Ltd CMP is 940.45. The Negative aspects of the company are High Valuation (P.E. = 69.2), FIIs are decreasing stake, High promoter pledge. The company's Positive aspects are No debt, MFs are increasing stake, improving annual net profit, improving cash from operations annual, Promoter holding increasing.
Entry for paper trading can be taken after closing above 945. Targets in the stock will be 970 and 1004. The long-term target in the stock will be 1020 and 1060. Stop loss in the stock should be maintained at Closing below 878.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
SPX 🗝Diversify YOUR Portfolio: EVERYONE Needs to Know❕📉Hi Traders, Investors and Speculators of Charts📈
HAVE YOU EVER CONSIDERED DIVERSIFYING YOUR PORTFOLIO?
Given the high risk nature of trading, having a finger in every pie is a good idea. Stocks generally are less volatile than crypto, and index funds are a great way to gain exposure to a variety of top notch stocks.
If you have ever wondered about trading stonks, today's update is for YOU. Cryptocurrencies are the largest part of our focus, but that doesn't mean we don't consider other markets such as forex, commodities and stocks. So today, let's take a look at the SPX / S&P 500.
Index investing, especially in the S&P 500, streamlines stock market engagement. Investing here means tapping into America's corporate giants, offering long-term returns and simplicity, often outperforming active stock picking. Since 1957, the S&P 500 has offered a global economic snapshot, including key international corporations. Its careful selection process reflects market trends, focusing on criteria like market cap and liquidity.
The top 4 stocks in the SPX by weight are :
1) Microsoft Corporation / NASDAQ:MSFT
2) Apple Inc. / $AAPLE
3) Nvidia Corp / NASDAQ:NVDA
4) Amazon.com Inc. / NASDAQ:AMZN
# Company Portfolio%
1 Microsoft Corp 7.14%
2 Apple Inc. 6.36%
3 Nvidia Corp 4.24%
4 Amazon.com Inc 3.65%
To put it into perspective, the last 4 stocks are:
500) NASDAQ:NWL / Newell Brands Inc. Producer Manufacturing
501) NYSE:DXC / DXC Technology Company Technology Services
502) NYSE:AAP / Advance Auto Parts Inc. Retail Trade
503) NYSE:TPR / Tapestry, Inc. Retail Trade / with a market cap of 4,017,225,400
(There are actually 503 stocks in the S&P500).
From the above, we can clearly conclude that what happens in those top 4 markets, holds quite a lot more weight than the rest. This should give you a clue which ones to look at if you want to invest in additional stocks and not necessarily a fund.
To correctly identify the macro phase is to have power - this will eliminate fear and greed, and cancel out the noise you hear from news and "influencers". Looking at SPX from a monthly perspective, we can clearly identify a strong bullish trend as the market loses makes what seems to be UP ONLY and keeps on making higher highs.
By using the S&P 500 or the AMEX:VTI , you can more easily spot the macro trend of the stock market, and which way MOST of the stocks will go, especially the top few.
If you found this content helpful, please remember to hit like and subscribe and never miss a moment in the markets.
_______________________
📢Follow us here on TradingView for daily updates📢
👍Hit like & Follow 👍
CryptoCheck
SP:SPX NASDAQ:MSFT NASDAQ:AAPL NASDAQ:NVDA NASDAQ:AMZN
Tata Elxsi giving encouraging signsTata Elxsi Ltd. is a global design and technology services company for product engineering and solution services across industries including Automotive, Broadcast, Communications, Healthcare, and Transportation. The operations are classified into two business divisions, i.e., Software Development and Services and Systems Integration and Support.
Tata Elxsi Ltd CMP is 7776.30. The Negative aspects of the company is High Valuation (P.E. = 60.8). The positive aspects of the company are Zero promoter pledge, FIIs are increasing stake, MFs are increasing stake, improving annual net profit, Improving cash from operations annual.
Entry can be taken after closing above 7858. Targets in the stock will be 8150 and 8591. The long-term target in the stock will be 8951 and 9188. Stop loss in the stock should be maintained at Closing below 7356.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
Marico might mend the trend..Marico Ltd. Is manufactures and markets products under the brands such as Parachute, Parachute Advansed, Nihar, Nihar Naturals, Saffola, Hair & Care, Revive, Mediker, Livon, Set-wet, etc. Marico’s products reach its consumers through retail outlets serviced by Marico’s distribution network comprising regional offices, carrying & forwarding agents, redistribution centers & distributors spread all over India. Marico Ltd CMP is 536.20.
The Negative aspects of the company are High Valuation (P.E. = 47.4), FIIs are decreasing stake, Promoter Holding decreasing. The company's Positive aspects MFs are increasing stake, improving annual net profit, Improving cash from operations annual.
Entry can be taken after closing above 537. Targets in the stock will be 554 and 563. The long-term target in the stock will be 575 and 592. Stop loss in the stock should be maintained at Closing below 508.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
Tube investment co can be smart investment Tube Investment of Investment Ltd. is one of India’s leading manufacturers of a wide range of products for major industries such as Automotive, Railway, Construction, Mining, Agriculture, etc. The Company’s 3 main verticals are Engineering, Metal Formed Products and Bicycles. In line with its growth strategies, the Company has forayed into TMT bars and Truck Body Building business and is additionally exploring opportunities in optic lens and other vision systems for the Auto industry.
Tube Investment Of Investment Ltd CMP is 3657.75. The Negative aspects of the company are High Valuation (P.E. = 53.5), FIIs are decreasing stake, Promoter Holding decreasing. The positive aspects of the company are No debt, Zero promoter pledge, MFs are increasing stake, Improving annual net profit, Improving cash from operations annual.
Entry can be taken after closing above 3678. Targets in the stock will be 3827 and 3955. The long-term target in the stock will be 4127. Stop loss in the stock should be maintained at Closing below 3437.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
Suven pharma can shine if it gets past the next resistance Suven Pharmaceuticals Ltd. is a bio-pharmaceutical company, incorporated on 6th November, 2018 and is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.
Suven Pharmaceuticals Ltd CMP is 669.65. The Negative aspects of the company are High Valuation (P.E. = 46), Declining annual net profit. The company's Positive aspects No debt, zero promoter pledge, FIIs are increasing stake, MFs are increasing stake, Improving cash from operations annual.
Entry can be taken after closing above 678. Targets in the stock will be 698 and 719. The long-term target in the stock will be 742 and 768. Stop loss in the stock should be maintained at Closing below 590.
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.
TWOU (2U bounce or kill learning )Ladies and gentlemen, esteemed educators, and future leaders,
As we stand on the cusp of a new era, the winds of change whisper promises of transformation and progress. In this age of relentless innovation, where the boundaries of possibility are constantly pushed, we find ourselves at the forefront of a revolution in education - the dawn of a new era in e-learning.
The future of education is not confined within the walls of traditional classrooms but stretches far beyond, into the limitless expanse of cyberspace. With each passing day, more universities join the ranks of pioneers, embracing the power of e-learning to redefine the landscape of higher education.
But what does this mean for us, for our future, and for the world we aspire to create? It means empowerment. It means access. It means opportunity.
Imagine a world where geographical barriers no longer dictate the pursuit of knowledge, where anyone, anywhere, can access world-class education with just a click. This is the promise of e-learning - a promise that transcends borders and levels the playing field for all who dare to dream.
As we embark on this journey, let us not forget the bright targets that beckon us forth. Let us envision a future where education is not just a means to an end but a beacon of hope, illuminating the path towards a brighter tomorrow.
In this future, every individual has the chance to unlock their full potential, to pursue their passions, and to carve out their own destiny. With the power of e-learning, we can equip ourselves with the knowledge and skills needed to tackle the challenges of the 21st century, to innovate, to create, and to shape a world that is fairer, more inclusive, and more prosperous for all.
But let us also remember that the true essence of learning extends beyond the confines of academia. It is not just about acquiring knowledge but about cultivating wisdom, empathy, and resilience. It is about embracing diversity, fostering collaboration, and nurturing a lifelong love for learning.
So, my friends, as we stand on the threshold of this brave new world, let us embrace the opportunities that lie ahead with courage and conviction. Let us seize the power of e-learning to propel ourselves towards a future where the pursuit of knowledge knows no bounds and where the brightest dreams of today become the reality of tomorrow.
Together, let us dare to dream, dare to learn, and dare to build a future that is as boundless as our imagination.
Thank you.
Tata Technologies Trying to bounce after forming a bottom. Tata Technologies Ltd. CMP – 1130.30 ( Long Term Investment Idea) (Potential Candidate for becoming a Portfolio Stock in future)
Market Capitalization Rs 45,852.7Cr
Red Flags:🔴
High Valuation
Declining cash from operations annual
Green Flags:🟢
No debt
Zero promoter pledge
FIIs are increasing stake
MFs are increasing stake
Improving annual net profit
Happy Candles Number – 42/100
X/2 Fresh Entry/ averaging / compounding after closing above 1132
Final Entry 1166
Targets: 1203, 1227 and 1257
Long term target: 1286, 1348 and 1404
Stop loss: Closing below 1070
The above information is provided for educational purpose, analysis and paper trading only. Please don't treat this as a buy or sell recommendation for the stock. We do not guarantee any success in highly volatile market or otherwise. Stock market investment is subject to market risks which include global and regional risks. We will not be responsible for any Profit or loss that may occur due to any financial decision taken based on any data provided in this message.